NICE backs Novartis' Adakveo via special channel despite 'high uncertainty' about cost, long-term efficacy | Fierce Pharma
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy | Journal of Law, Medicine & Ethics | Cambridge Core
FDA Panel Votes Unanimously to Support Leukemia Gene-Therapy Treatment - WSJ
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients | Fierce Pharma
ASCO: Gilead's Kite soars over Novartis' CAR-T turf with Tecartus win in type of leukemia | Fierce Pharma
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites | Cell Death & Disease
Gene Therapy Reviews Return To US FDA Advisory Committee Schedule :: Pink Sheet
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell | Nature Medicine
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
ONCOLOGIC DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT Tisagenlecleucel (CTL019) for the TREATMENT OF PEDIATRIC AND YOUNG ADULT PA
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas | Nature Medicine
Non-viral precision T cell receptor replacement for personalized cell therapy | Nature
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
FDA Introductory Remarks Tisagenlecleucel Novartis Pharmaceuticals Corporation
Frontiers | Manufacturing and Management of CAR T-Cell Therapy in “COVID-19's Time”: Central Versus Point of Care Proposals
Can CAR-T and gene therapy cures really sustain biopharma? Not for all, analyst says | Fierce Pharma
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma | Nature Communications
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
CAR T-cell treatment pathway: From patient identification to long-term management - touchONCOLOGY
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19 - Cytotherapy
